Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A, Gomez-Roca C, Chabaud S, Rodriguez C, Nkodia A, Berthet J, Montane L, Bidaux AS, Treilleux I, Eberst L, Terret C, Korakis I, Garin G, Pérol D, Delord JP, Caux C, Dubois B, Ménétrier-Caux C, Bendriss-Vermare N, Cassier PA. Voissière A, et al. Among authors: eberst l. Sci Transl Med. 2024 Jan 24;16(731):eadd1834. doi: 10.1126/scitranslmed.add1834. Epub 2024 Jan 24. Sci Transl Med. 2024. PMID: 38266104
Complete Laparoscopic Interval Debulking Surgery for Advanced Ovarian Cancer Achieves Similar Survival Outcomes to Open Approach: A Propensity-Matched Study.
Lecointre L, Pellerin M, Venkatasamy A, Fabacher T, Eberst L, Gantzer J, Jochum F, Faller É, Boisramé T, Querleu D, Akladios C. Lecointre L, et al. Among authors: eberst l. J Invest Surg. 2022 Jun;35(6):1394-1401. doi: 10.1080/08941939.2022.2045396. Epub 2022 Mar 1. J Invest Surg. 2022. PMID: 35227150
[Therapeutic targeting of Notch signaling in cancer].
Brahmi M, Bally O, Eberst L, Cassier P. Brahmi M, et al. Among authors: eberst l. Bull Cancer. 2017 Oct;104(10):883-891. doi: 10.1016/j.bulcan.2017.07.007. Epub 2017 Oct 12. Bull Cancer. 2017. PMID: 29031504 Review. French.
[DNA repair as a therapeutic target].
Eberst L, Brahmi M, Cassier PA. Eberst L, et al. Bull Cancer. 2017 Nov;104(11):988-998. doi: 10.1016/j.bulcan.2017.09.005. Epub 2017 Nov 11. Bull Cancer. 2017. PMID: 29132681 Review. French.
Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor.
Verspoor FGM, Mastboom MJL, Hannink G, Maki RG, Wagner A, Bompas E, Desai J, Italiano A, Seddon BM, van der Graaf WTA, Blay JY, Brahmi M, Eberst L, Stacchiotti S, Mir O, van de Sande MAJ, Gelderblom H, Cassier PA. Verspoor FGM, et al. Among authors: eberst l. Sci Rep. 2019 Oct 10;9(1):14551. doi: 10.1038/s41598-019-51211-y. Sci Rep. 2019. PMID: 31601938 Free PMC article.
Uncovering the Translational Regulatory Activity of the Tumor Suppressor BRCA1.
Berthel E, Vincent A, Eberst L, Torres AG, Dacheux E, Rey C, Marcel V, Paraqindes H, Lachuer J, Catez F, Pouplana LR, Treilleux I, Diaz JJ, Venezia ND. Berthel E, et al. Among authors: eberst l. Cells. 2020 Apr 10;9(4):941. doi: 10.3390/cells9040941. Cells. 2020. PMID: 32290274 Free PMC article.
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Saleh M, Cassier PA, Eberst L, Naik G, Morris VK, Pant S, Terret C, Gao L, Long A, Mao H, McNeely S, Wagner EK, Carlesi RM, Fu S. Saleh M, et al. Among authors: eberst l. Oncologist. 2020 Nov;25(11):e1628-e1639. doi: 10.1634/theoncologist.2020-0520. Epub 2020 Jul 17. Oncologist. 2020. PMID: 32537847 Free PMC article. Clinical Trial.
32 results